Pelanserin

Pelanserin
Clinical data
Other namesTR2515; TR-2515
Routes of
administration
Oral
Drug classSerotonin 5-HT2A receptor antagonist; α1-Adrenergic receptor antagonist
ATC code
  • None
Pharmacokinetic data
Onset of action<1 hour (TmaxTooltip time to peak levels)
Elimination half-life3.8 hours
Identifiers
  • 3-[3-(4-phenylpiperazin-1-yl)propyl]quinazoline-2,4(1H,3H)-dione
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H24N4O2
Molar mass364.449 g·mol−1
3D model (JSmol)
  • C1CN(CCN1CCCN2C(=O)C3=CC=CC=C3NC2=O)C4=CC=CC=C4
  • InChI=1S/C21H24N4O2/c26-20-18-9-4-5-10-19(18)22-21(27)25(20)12-6-11-23-13-15-24(16-14-23)17-7-2-1-3-8-17/h1-5,7-10H,6,11-16H2,(H,22,27)
  • Key:WPKPLSFHHBBLRY-UHFFFAOYSA-N

Pelanserin (developmental code name TR-2515) is a serotonin 5-HT2 and α1-adrenergic receptor antagonist which was under development for the treatment of hypertension but was never marketed. Its development was discontinued in 2001.

Pharmacology

Pharmacokinetics

The pharmacokinetics of pelanserin have been studied. It has a relatively short elimination half-life. The drug's time to peak levels was less than 1 hour and its half-life was 3.8 hours in a single subject in an analytical study.

Chemistry

Synthesis

Synthesis of pelanserin

Pelanserin (3) can be synthesized by a reaction between isatoic anhydride (1) and 1-(3-aminopropyl)-4-phenylpiperazine (2) in the presence of phosgene.

See also